688298 东方生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入182,922-51.36%820,1578,767,93810,169,1683,265,356
减:营业总成本286,549-32.46%1,002,2995,068,0434,367,2031,206,652
    其中:营业成本123,746-51.08%467,4034,314,3992,665,325677,778
               财务费用(35,094)3,645.95%(275,581)(603,272)67,23957,790
               资产减值损失(3,251)-108.64%(236,509)(1,209,740)(16,671)(75,467)
公允价值变动收益28,146-3,127.97%(8,990)1,66044--
投资收益15,27843.84%42,0146,02311,14815,008
    其中:对联营企业和合营企业的投资收益(861)357.76%(1,498)1,914----
营业利润(67,455)4,565.92%(383,835)2,528,2105,776,3991,974,346
利润总额(68,117)80.90%(404,227)2,470,7525,769,9661,974,281
减:所得税费用1,838-79.01%14,042373,321829,320293,950
净利润(69,955)50.72%(418,269)2,097,4314,940,6461,680,331
减:非控股权益(2,602)-166.42%(20,685)29,71720,4582,972
股东净利润(67,353)33.82%(397,584)2,067,7144,920,1881,677,359

市场价值指针
每股收益 (元) *-0.33010.00%-1.97012.31041.00014.280
每股派息 (元) *------2.0006.1804.200
每股净资产 (元) *36.511-24.26%36.88548.58857.14320.384
审计意见 #----标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容